The Synairgen share price (LON: SNG) ended the week up higher by 53 percent as the realities of COVID-19 continue to be highlighted in society.
Earlier in the week Synairgen revealed that in vitro studies shown promise in the ability for its unique treatment to fight against COVID-19 variants including the Kent variant and the South African variant.
In an update to the market, it revealed that while the vaccine rollout is promising, it is unlikely to be the end of the matter as variants spread and the vaccine does not provide complete protection to all.
You can read about this here ( Synairgen share price surges on COVID-19 variant promise ).
And as the week unfolded we continued to see the credibility of this claim.
Today the UK has announced that it has over 4,000 COVID-19 cases with the majority believed to be due to the Indian variant with the spread assisted by various restrictions being lifted during May.
This is the highest number of cases since 1 April.
COVID-19 stocks: A faster roll-out is key to sustaining momentum
Investing in COVID-19 stocks seems something of a familiar story.
When cases are low and things appear to be moving forward, they lose their momentum.
However, when the reality of the situation unfolds, they can quickly come back into fashion.
The key for the COVID-19 related stocks of hot-investor interest will be to start delivering practically. Synairgen needs to get its treatment approved and out into the market, Avacta similar and of course Omega Diagnostics needs the government to give it a test to produce – any will do as it has relayed.